VAXCEL LIGNOCAINE 2% INJECTION

Quốc gia: Malaysia

Ngôn ngữ: Tiếng Anh

Nguồn: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

Thành phần hoạt chất:

Lignocaine Hydrochloride

Sẵn có từ:

KOTRA PHARMA (M) SDN. BHD.

INN (Tên quốc tế):

Lignocaine Hydrochloride

Các đơn vị trong gói:

10 mL; 10ml mL

Sản xuất bởi:

KOTRA PHARMA (M) SDN. BHD.

Tờ rơi thông tin

NONE
id10225296 pdfMachine by Broadgun Software - a great PDF writer! - a
great PDF creator! - http://www.pdfmachine.com http://www.broadgun.com

Đặc tính sản phẩm

COMPOSITION:
Each ml contains
Lignocaine Hydrochloride 20mg
PRESENTATION:
Clear, colorless solution, essentially free from
visible evidence of contamination.
INDICATIONS:
For local or regional anaesthesia, peripheral
nerve
block,
infiltration
anaesthesia
and
diagnostic or therapeutic block.
MECHANISMS OF ACTION:
Lignocaine is local anaesthetics of the amide
type which is thought to act within the sodium
channels of the nerve membrane. Like other
local
anaesthetics,
it
causes
reversible
blockade of impulse propagation along nerve
fibers by preventing the inward movement of
sodium ions through the nerve membrane. It
produces
reversible
loss
of
sensation
by
preventing or diminishing the conduction of
sensory nerve impulses near the site of their
application. Lignocaine is readily absorbed
through mucous membrane. It exerts its effect
in the form of non-ionised base. It tends to
interfere with the process to the generation of
the nerve action potential namely the large
transient increase in the permeability of the
membrane to sodium ions that is produced by
a slight depolarization of the membrane. As
the anaesthetic action progressively develops
in
a
nerve,
the
threshold
for
electrical
excitability gradually increases and the safety
factor for conduction decreases. When this
action is sufficiently well developed, block of
conduction is produced.
PHARMACOKINETICS:
Following
intravenous
injection,
the
blood
level of lignocaine declines with a half-life of
seven to ten minutes within the first half hour
due to a rapid distribution into various tissues
including the heart. After this initial phase, the
half-life is 90-120 minutes (metabolism and
excretion). During a continuous infusion, the
steady state is achieved after six to eight
hours. Metabolism is mainly by N-dealkylation
and hydrolysis in the liver. Excretion is via the
kidneys. Approximately 90% of the dose is
excreted as metabolites and less than 10% is
excreted
unchanged.
The
principal
metabolites
also
possess
antiarrhythmic
activity, but to a lesser extent.
D